日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. CD80 (Galiximab Biosimilar) Recombinant Monoclonal Antibody

CD80 (Galiximab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA004959MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CD80(Galiximab Biosimilar Antibody)重組單克隆抗體是一種針對CD80分子的特異性單克隆抗體，主要用于生命科學領域的基礎研究與機制探索。CD80作為重要的共刺激分子，廣泛表達于樹突狀細胞、活化B細胞及巨噬細胞表面，通過與T細胞表面的CD28或CTLA-4受體結(jié)合，調(diào)控T細胞的活化、增殖與分化過程，在免疫應答的啟動和調(diào)節(jié)中發(fā)揮關(guān)鍵作用。 該抗體通過重組DNA技術(shù)在哺乳動物細胞中表達，經(jīng)Protein A親和層析、離子交換層析等多步純化工藝制備，具有高純度、高特異性和良好的生物學活性。其分子結(jié)構(gòu)包含完整的免疫球蛋白G（IgG）框架，可變區(qū)能夠精準識別CD80分子的胞外結(jié)構(gòu)域，可通過某些實驗技術(shù)，實現(xiàn)對細胞表面或組織中CD80分子的定性檢測、定量分析及定位研究。 在科研應用中，CD80重組單克隆抗體可用于探索CD80-CD28/CTLA-4信號通路在自身免疫性疾病、腫瘤免疫逃逸及移植排斥等過程中的作用機制，助力揭示免疫調(diào)節(jié)的分子基礎。同時，該抗體也可作為工具試劑，用于CD80陽性細胞的分選與鑒定，或與其他免疫分子抗體聯(lián)合使用，構(gòu)建復雜免疫微環(huán)境的研究模型。其嚴格的質(zhì)量控制確保了實驗結(jié)果的可靠性與可重復性，為免疫生物學、腫瘤學及轉(zhuǎn)化醫(yī)學等領域的研究提供有力支持。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Anti-B7.1-MAb research-grade biosimilar; Anti-CD80 monoclonal antibody research-grade biosimilar; Galiximab research-grade biosimilar; Galiximab (USAN/INN) research-grade biosimilar; IDEC 114 research-grade biosimilar; IDEC-114 research-grade biosimilar; IDEC 114-20 research-grade biosimilar; IDEC-114-20 research-grade biosimilar ;CD80 antibody; CD28LG antibody; CD28LG1 antibody; LAB7 antibody; T-lymphocyte activation antigen CD80 antibody; Activation B7-1 antigen antibody; BB1 antibody; CTLA-4 counter-receptor B7.1 antibody; B7 antibody; CD antigen CD80 antibody
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human CD80 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.; (Microbial infection) Acts as a receptor for adenovirus subgroup B.
  • 基因功能參考文獻：
    1. Addition of TNFalpha to podocytes causes CD80 upregulation, actin reorganization and podocyte injury. PMID: 29022109
    2. Urinary CD80 levels were significantly higher in the children with minimal change disease than in the controls and patients with other causes of nephrotic syndrome. PMID: 29507273
    3. Results showed novel genetic associations with bone phenotypes and points to the CD80 gene as relevant in postmenopausal bone loss. PMID: 28466138
    4. Increased expressions of TLR-3, TLR-4 and CD80 mRNA and the level of urinary CD80/creatinine could be useful markers to differentiate patients of steroid-sensitive nephrotic syndrome in relapse from those with steroid-resistant nephrotic syndrome. PMID: 28210837
    5. The rs1915087 (C>T), rs6804441 (A>G) and rs41271391 (G>T) of B7 antigens were suspected as the factors associated with reduced risk of recurrent spontaneous abortion. PMID: 29069644
    6. Tregs were observed to regulate CD4(+), but not CD8(+), T cell infiltration into tumors through a CTLA-4/CD80 dependent mechanism. Disrupting CTLA-4 interaction with CD80 was sufficient to induce CD4 T cell infiltration into tumors. PMID: 28856392
    7. Results show that CD80 down-regulation is associated to aberrant DNA methylation in dysplasia of sporadic colonic carcinogenesis. This study indicates that the failure of immune surveillance mechanisms in non-inflammatory colon carcinogenesis may be linked to genomic methylation directly or indirectly affecting CD80 expression. PMID: 27377375
    8. Fabry disease is characterized by early occurrence of increased uCD80 excretion that appears to be a consequence of glycolipid accumulation. PMID: 27733175
    9. CTLA-4(+) microvesicles can competitively bind B7 costimulatory molecules on bystander dendritic cells, resulting in downregulation of B7 surface expression. PMID: 26979751
    10. The expression of B7-H6 is up-regulated in U87-derived glioma stem like cells. PMID: 27609569
    11. PD-1 receptor has a role in interacting with programmed cell death ligands and B7-1 PMID: 28270509
    12. CD80-QPAR platform provides a useful predictive model for unknown RA extract's bioactivities using the chemical fingerprint inputs PMID: 28337449
    13. this study shows that dendritic cells from rheumatoid arthritis patients have low expression levels of CD80 PMID: 27421624
    14. B7-1 is not expressed by podocytes in LN. A renoprotective effect of B7-1 blockade in LN patients cannot be ruled out but, if confirmed, cannot be the result of an effect on podocyte B7-1 PMID: 27198457
    15. analysis of CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease [review] PMID: 26409459
    16. Genetic interaction of CD80 and ALOX5AP was observed in systemic lupus erythematosus in Asian populations. PMID: 25862617
    17. Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression PMID: 27065104
    18. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vgamma9Vdelta2 T cells in low levels of IL-2. PMID: 26561569
    19. B7-1 is not induced in podocytes from patients with minimal change disease or focal segmental glomerulosclerosis. PMID: 26697986
    20. In the present study, we investigated the prognostic significance of the expression of three genes in the PD-L1 pathway, including PD-L1, B7.1 and PD-1, in three independent bladder cancer datasets in the Gene Expression Omnibus database. PMID: 25963805
    21. SNP rs1599795 in CD80 3'-UTR, through disrupting the regulatory role of miR-132-3p, miR-212-3p, and miR-361-5p in CD80 expression, contributed to the occurrence of gastric cancer. PMID: 24981235
    22. Meningococcal capsular polysaccharide-loaded vaccine nanoparticles induce expression of CD80. PMID: 24981893
    23. These findings reveal the distinct but complementary roles of CD80 and CD86 IgV and IgC domains in T cell activation. PMID: 24845157
    24. Expression of costimulatory molecules CD80/86 is an absolute requirement for efficient CD8 T cell priming by adenoviral vectors. PMID: 24951814
    25. Single-nucleotide polymorphisms in CD80 gene is associated with breast cancer risk after menopausal hormone replacement therapy. PMID: 24080446
    26. Data indicate that STAT5A and STAT5B transcription activator complex induces expression of CD80 gene. PMID: 24523507
    27. NOTCH1 protein regulates CD80/CD86-induced phosphatidylinositol 3-kinase signaling in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells PMID: 24415757
    28. lower expression on CD1c+ myeloid and CD303+ plasmacytoid DCs in pre-eclampsia PMID: 23773232
    29. No role in CD80 expression by podocytes was found for cytokines released by peripheral blood mononuclear cells PMID: 23689904
    30. Data indicate that low-dose decitabine (DAC) treatment can induce CD80 gene expression in a variety of cancer cells. PMID: 23671644
    31. These studies identify CD80-Fc as an alternative and potentially more efficacious therapeutic agent for overcoming PDL1-induced immune suppression and facilitating tumor-specific immunity PMID: 23918985
    32. Data indicate that the frequencies of CD11c, CD11c/CD86, HLA-DR/CD86, CD83 and CD80 were significantly high, while CD11c/HLA-DR was low in Hepatitis E infection. PMID: 23246582
    33. Lower expression of B7-1 and B7-2 proteins on peripheral monocytes in pre-eclampsia might indicate a secondary regulatory mechanism in response to the ongoing systemic maternal inflammation. PMID: 23289444
    34. he aim of this work was to analyse the interaction between early events in colonic ulcerative colitis-related and non-inflammatory carcinogenesis and CD80 expression to clarify what stimuli induce its up-regulation in these patients. PMID: 22704122
    35. mRNA expression analysis of B7-1 and NPHS1 in urinary sediment may be useful to differentiate between different histologic subtypes of glomerular kidney disease, particularly between minimal change disease and focal segmental glomerulosclerosis. PMID: 21414970
    36. Data suggest that expression of CD80, CD86, and CD40 on dendritic cells in normal endometrium is higher than on tumor infiltrating dendritic cells in endometrioid adenocarcinoma; this may reflect roles in antigen presentation/tumor escape. PMID: 22142817
    37. Data show that CD80 promoter and CD86 exon 8 allele frequencies vary significantly among populations of different ancestries. PMID: 22074996
    38. The interaction between PDL1 on antigen prresenting cells and B7.1 on T cells plays a dominant role in bidirectional interactions between these two molecules during alloimmune responses. PMID: 21697455
    39. the expression of the co-stimulatory molecule CD80 was decreased in intestines of celiac disease children after gluten-free diet. PMID: 21288140
    40. the costimulatory molecule CD80 prevents PDL1-mediated immune suppression by tumor cells and restores T cell activation PMID: 21555531
    41. Efficiency of GHA priming chemotherapy on refractory acute myeloid leukemia and myelodysplastic syndrome may be correlated with B7.1 expression. PMID: 18928583
    42. The low expression of CD80 and CD86 in thyroid papillary carcinoma may help them evade the immune system. PMID: 21469977
    43. study shows CTLA-4 can capture its ligands (CD80, CD86)from opposing cells by trans-endocytosis; data reveal mechanism of immune regulation in which CTLA-4 acts as an effector molecule to inhibit CD28 costimulation by cell-extrinsic depletion of ligands PMID: 21474713
    44. These results suggest that the polymorphisms of the CD86 gene may be used as genetic markers for making the diagnosis and prognosis of Graves' ophthalmopathy. PMID: 20884055
    45. Thalidomide can up-regulate the expression of B7-1 molecules on myeloma cells. PMID: 20034904
    46. increased CD80 and CD86 expression with the progression of tubulointerstitial lesion might play an important role in the development of lupus nephropathy PMID: 20979791
    47. B7-1 costimulation is required for induction and maintenance of lymphocytic choriomeningitis virus (LCMV)-specific CD8+ T cell memory, in T cell receptor (TCR)transgenic mice. PMID: 20601595
    48. B7-H1 and B7-1 significantly correlated with the pathological grade and tumor-node-metastasis (TNM) stage, respectively in pancreatic cancer. PMID: 20145927
    49. Data show that pollen grains triggered the production of IL-8, TNF-alpha, IL-6 and strongly upregulated the membrane expression of CD80, CD86, CD83, HLA-DR and caused only a slight increase in the expression of CD40. PMID: 20118277
    50. Thus, this study is the first demonstration of a distinct signaling event induced by CD80 and CD86 molecules in B cell lymphoma. PMID: 11726649

    顯示更多

    收起更多

  • 亞細胞定位：
    Membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed on activated B-cells, macrophages and dendritic cells.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 1700

    OMIM: 112203

    KEGG: hsa:941

    STRING: 9606.ENSP00000264246

    UniGene: Hs.838



×
生命科學計算平臺